Abstract:Background Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. Methods The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p < 1 x 10(-5)) were tested in a validation cohort comprising patients from the Chinese Antipsychotics Pharmacogenetics Consortium from five collaborative hospitals, who were treated with olanzapine, risperidone, or aripiprazole for 8 weeks. Findings The discovery cohort contained 2413 patients and the validation cohort 1379 patients. In the discovery cohort, we identified three novel SNPs (rs72790443 in MEGF10 [p=1.37 x 10(-8)], rs1471786 in SLC1A1 [p=1.77 x 10(-8)], and rs9291547 in PCDH7 [p=4.48x 10(-8)]) that were associated with antipsychotic treatment response at a genome-wide significance level. These associations were confirmed in the validation cohort (p < 0.05). In the combined sample of the discovery and validation cohorts, we identified five novel loci showing genome-wide significant associations with general antipsychotic treatment response (rs72790443 in MEGF10 [p=1.40 x 10(-9)], rs1471786 in SLC1A1 [p=2.33 x 10(-9)], rs9291547 in PCDH7 [p=3.24 x rs9291547 in PCDH7 [p=3.24 x 10(-9)], rs12711680 in CNTNAP5 [p=2.12 x 10(-9)], and rs6444970 in TNIK [p=4.85 x 10(-8)]).], rs12711680 in CNTNAP5 [p=2.12 x 10(-8)], and rs6444970 in TNIK [p=4.85 x 10(-8)]). In antipsychotic-specific groups, after the combination of results from both samples, the rs2239063 SNP in CACNA1C was associated with treatment response to olanzapine (p=1.10 x 10(-8)), rs16921385 in SLC1A1 was associated with treatment response to risperidone (p=4.40 x 10(-8)), and rs17022006 in CNTN4 was associated with treatment response to aripiprazole (p=2.58 x 10(-8)). Interpretation We have identified genes related to synaptic function, neurotransmitter receptors, and schizophrenia risk that are associated with response to antipsychotics. These findings improve understanding of the mechanisms underlying treatment responses, and the identified biomarkers could eventually guide choice of antipsychotic in patients with schizophrenia.

Contribution of copy number variants on antipsychotic treatment response in Han Chinese patients with schizophrenia

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Association of Telomere Length and Mitochondrial DNA Copy Number with Risperidone Treatment Response in First-Episode Antipsychotic-Naïve Schizophrenia

Association Studies of Genomic Variants with Treatment Response to Risperidone, Clozapine, Quetiapine and Chlorpromazine in the Chinese Han Population

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients.

Five Novel Loci Associated with Antipsychotic Treatment Response in Patients with Schizophrenia: a Genome-Wide Association Study

Genome-wide Analysis of the Role of Copy Number Variation in Schizophrenia Risk in Chinese

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Association Analysis of ZNF804A (zinc Finger Protein 804A) Rs1344706 with Therapeutic Response to Atypical Antipsychotics in First-Episode Chinese Patients with Schizophrenia.

Meta-Analysis of Genome Wide Association Studies Showed Polymorphisms on 2P16.1, 6P22.1 and 10Q24.32 Associated with Schizophrenia in Chinese Han Population

Novel Association Strategy with Copy Number Variation for Identifying New Risk Loci of Human Diseases

Association Analysis and Polygenic Risk Score Evaluation of 38 Gwas-Identified Loci in A Chinese Population with Parkinson'S Disease

Progress in Genome-Wide Association Studies of Schizophrenia in Han Chinese Populations.

P.1.04 Schizophrenia and Cytogenetic Aberrations: in Search of Susceptibility Genes and Pathways

Different Responses to Risperidone Treatment in Schizophrenia: a Multicenter Genome-Wide Association and Whole Exome Sequencing Joint Study

The correlation between CYP2D6 gene polymorphisms and clinical response of risperidone treatment in Chinese Han schizophrenia patients

Genome-wide study of copy number variation implicates multiple novel loci for schizophrenia risk in Han Chinese family trios

Combined Study of Genetic and Epigenetic Biomarker Risperidone Treatment Efficacy in Chinese Han Schizophrenia Patients

Two Novel Loci of RELN Associated with Antipsychotics Response in Chinese Han Population

Association of multidrug resistance 1 gene polymorphism with the clinical efficacy of paliperidone and risperidone in schizophrenic patients

Functional Magnetic Resonance Imaging in a Single Schizophrenia Patient with Voluntary Control over Auditory Verbal Hallucinations